After adjusting for age, gender, body mass index, previous VTE, ipsilateral recurrent DVT, extent of DVT, idiopathic DVT, duration of anticoagulant treatment, compliance to assigned study medication, elastic compression stocking use, and active malignancy, the outcome did not reach statistical significance, the HR of PTS development for rivaroxaban was 0.76 (95% CI: 0.51‐1.13). 73 3.2.1 ISTH Berlin 2017 reports In a cross‐sectional study Utne and collaborators assessed whether treatment with rivaroxaban might have lowered the rate of PTS compared to warfarin treatment. 74 The 2‐year rate of PTS for patients treated with rivaroxaban and patients treated with enoxaparin/warfarin was compared.
1
—
—